Sun et al. developed a tumor-targeted nanoplatform (OMV/SaFeFA) by engineering bacterial outer membrane vesicles (OMVs) with Fe2+ ions, a STING agonist (agonist-4), and folate receptor-targeting DSPE-PEG-FA [154] (Fig. 20). This evidence concerns the gene STING1 and neoplasm.